ROPINIROLE VERSUS LEVODOPA: BETTER CLINICAL BENEFITS IN PARKINSON’S DISEASE
نویسندگان
چکیده
Parkinson’s disease is a progressive, neurodegenerative disorder of the extrapyramidal nervous system affecting mobility and control skeletal muscular system. Although PD can develop at any age, it begins most commonly in older adults, with peak age onset around 60 years. Levodopa dopamine agonists such as ropinirole are used treatment. This complete literature search was done using Google Scholar PubMed. review to compare safety efficacy that Levodopa.
منابع مشابه
Levodopa versus non-levodopa brain language fMRI in Parkinson's disease.
OBJECTIVE To identify the effect of levodopa in language areas in Parkinson's disease patients. METHODS We evaluated 50 patients with mild to moderate Parkinson's disease, age and gender paired to 47 healthy volunteers. We selected two homogeneous groups of 18 patients taking levodopa and 7 no levodopa patients. The functional magnetic resonance imaging verbal fluency task, with low and high ...
متن کاملSleepiness and Depression in Parkinson’s Disease Patients Treated with Ropinirole and Levodopa
OBJECTIVE We aimed to investigate the effect of ropinirole on excessive daytime sleepiness (EDS) and depression in Parkinson's disease (PD) with a large population. METHODS We conducted a cross-sectional observational study at nine hospitals in Korea between April 24, 2013, and April 22, 2015. We analyzed the demographic and clinical features, other medical history, history of antiparkinsonia...
متن کاملRopinirole therapy for Parkinson's disease.
Ropinirole (Requip, GlaxoSmithKline) is a novel nonergoline dopamine D2 agonist indicated for the treatment of early and advanced Parkinson's disease. It is mainly metabolized by the liver and its elimination half-life is approximately 5.8 h. When used as monotherapy in early Parkinson's disease, ropinirole improves signs and symptoms of the disorder. When used as an adjunct to levodopa in adva...
متن کاملComparison of once-daily versus twice-daily combination of Ropinirole prolonged release in Parkinson’s disease
BACKGROUND Ropinirole prolonged release (RPR) is a once-daily formulation. However, there may be individual pharmacokinetic differences so that multiple dosing may be preferred in some individuals. This study compares once-daily and twice-daily RPR in patients with Parkinson's disease. METHODS This study was an open-label crossover study. We enrolled Parkinson's disease patients on dopamine a...
متن کاملFor better or worse: The effect of levodopa on speech in Parkinson's disease.
While the beneficial effect of levodopa on traditional motor control tasks have been well documented over the decades, its effect on speech motor control has rarely been objectively examined and the existing literature remains inconclusive. This paper aims to examine the effect of levodopa on speech in patients with Parkinson's disease. It was hypothesized that levodopa would improve preparator...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of applied pharmaceutical sciences and research
سال: 2022
ISSN: ['2581-5520']
DOI: https://doi.org/10.31069/japsr.v5i3.02